loader image

The Power of Global Alliances

With their growing strategic collaborations across Europe, Asia, and North America, cellNUA is actively developing two additional powerful platforms to address the complex challenges around Longevity and Brain Health, multiple patents have been submitted.

Because the need for combining forces and developing universal platforms against threats remains critical, the cellNUA executive team is in strategic alliance discussions with four additional leading academic institutions and will include scope of work in each of their areas of focus: Immunology and vaccine development, Longevity, and Brain Health.

Recognizing the significance of the work cellNUA is undertaking, the UK government approved grant funding – in conjunction with Centre for Process Innovation (CPI), a leading independent technology innovation centre and a founding member of the UK Government’s High Value Manufacturing Catapult; this funding extended across all three of their ground-breaking healthcare platforms in Immunology and vaccine development, Longevity, and Brain Health.


cellNUA’s goal of universal access to the BEEMAR™ technology platform took a major step forward in 2022 with the establishment of its first African architecture, providing end-to end healthcare preparedness in Ghana.

Partnering with the highly acclaimed Noguchi Memorial Institute for Medical Research (NMIMR), (University of Ghana) the first cellNUA hives were successfully populated with wild African bees in Q2 2022. Extraction protocols and capabilities were locally refined with first in-vitro laboratory tests carried out in Q3 2022. Following ethical approval, pre-clinical trials competed Q4 2022, representing a major step in preparing Regulatory submissions for a ground-breaking Malaria treatment for the FDA in Ghana. Furthering the company’s objective of a flexible and agile platform, NMIMR are targeting pathogens of most concern to local populations, and in particular AIDS and malaria, along with more globally important diseases such as Corona- and flu-viruses.


cellNUA adopt a CIRCULAR ECOSYSTEM APPROACH to all medical innovations and have built an international team of academic and scientific collaborators to ensure the highest standards in safety and efficacy. Although times have changed, more than half of the world’s population still relies exclusively on animal chain supply for medications; a supply that is becoming increasingly rare.

Up to 70 is the percentage of medicinal products that contain substances of animal origin or for which this origin cannot be excluded based on the information available to the public (Source: Tatham K and Patel K. Why can’t all drugs be vegetarian? (BMJ 2013;346:f722)).

Join the Movement

Be the first to know what’s happening